Biogen to acquire Nightstar Therapeutics in a deal worth $800m to target retinal diseases

In a significant move within the biotech sector, Biogen, the US-based biotechnology giant, has announced its agreement to acquire Nightstar Therapeutics, a UK-based clinical-stage gene ... Read More